上天天基金APP搜索777注册即可领500元券包，优选基金10元起投！限量发放！先到先 得！ 第一，放弃"一夜暴富"的想法，拥抱长期主义 。避免陷入"追题材、炒小票、加杠杆"三大致 命陷阱。 8月26日，A股三大指数集体低开，午后翻红。 板块方面， 人工智能、算力涨幅居前 。开普云、拓维信息、天融信等涨停。东方证券表示， 国内AI大模型频频取得突破、国产AI芯片、国产交换芯片性能持续提升，我国AI算力、AI应 用、国产交换芯片有望得到持续发展。投资者们对我国AI发展的信心亦有望持续提升。 游戏股逆势走强 ，三七互娱涨停，恺英网络、完美世界、巨人网络等跟涨。消息面上，国家 新闻出版署正式公布2025年8月游戏版号审批结果，共166款国产网络游戏和7款进口网络游戏 获批，单月总量达173款，刷新年内新高。 芯片股出现调整 ，芯原股份跌超7%，寒武纪跌超3%，云天励飞、海光信息等跟跌。 创新药小幅回调 ，济民健康、申联生物跌超3%。湘财证券指出，2025 年国内创新药产业迎来 拐点，产业运行趋势由资本驱动转向盈利驱动，在基本面及政策持续推动下，板块业绩与估值 双重修复趋势有望延续。 牛市投资者"生存指南" 在当前行 ...

将投中网设为"星标⭐"，第一时间收获最新推送 硬科技赛道 ，"空天科技"成为新风口。 上周，北京穿越者载人航天科技有限公司正式宣布完成天使 +轮超募融资，由启迪之星创投加投。此外，追梦空天科技也在近日宣布连续完成两轮合计超亿元 Pre-A++轮及战略轮融资。Pre-A++轮融资由朝希资本领投，钧山资本、莫干山基金、海邦沣华等 机构跟投，老股东晓池资本持续跟投；战略轮融资由航投基金独家投资。 大健康赛道，合成生物学受青睐。 上周，合成生物学企业微远生物已成功完成近亿元Pre-A轮融 资。本轮融资由熔拓资本领投，道彤投资跟投，种子轮老股东大晶创投、真石资本持续坚定追加投 资。与此同时，合成生物学企业苏州一兮生物宣布完成近2亿元A轮融资，本轮融资由黄山新安江资 本投资管理有限公司管理的黄山供赢一兮股权投资基金投资。 互联网赛道，AI投资聚焦"应用层"。 上周，情感语音交互模型初创公司宇生月伴近日完成新一轮融 资，由靖亚资本和小苗朗程领投，菡源资产（上海交大母基金）跟投，心流资本FlowCapital担任长 期财务顾问。此外，ChatExcel 团队近日已完成近千万天使轮融资。此次融资由上海常垒资本、武 汉东湖天使基 ...

Group 1 - Huayi Family plans to invest up to 300 million CNY to acquire 5%-8.09% of Haihe Pharmaceutical's shares, marking a significant move after years of inactivity in external investments [1] - Haihe Pharmaceutical has successfully commercialized three products, including Gumeitini tablets, which received conditional approval in March 2023 and was included in the national medical insurance directory [2] - The company has a strong pipeline with five products in clinical research, including a PI3Kα inhibitor, indicating potential for growth in unmet clinical needs [3] Group 2 - The domestic innovative drug industry is accelerating, with small molecule drugs maintaining an irreplaceable position in clinical treatment due to their convenience and cost-effectiveness [4] - Huayi Family's investment in Haihe Pharmaceutical is a strategic move to optimize its business structure amid challenges in the real estate sector, aiming for predictable returns as Haihe Pharmaceutical is expected to enter a rapid growth phase by 2027 [4] - This investment reflects Huayi Family's recognition of Haihe Pharmaceutical's R&D capabilities and commercial prospects, serving as a crucial step for future business transformation [4]

迪哲医药 20250824 摘要 迪哲医药舒尔哲（舒沃替尼）获 FDA 加速批准上市，成为全球首个用于 易介发 20 插入的小细胞肺癌口服 EGFR TKI，并迅速被纳入美国 NCCN 指南，且在中国主要指南中获得最高级别推荐，为公司带来显著的市场 先发优势。 迪哲医药 8,586 项目作为全球首个宁和 BTK 双通道抑制剂，在 ASCO 大会上首次亮相并被选为大会口头报告，展示了其在 CLL 和 SLL 治疗中 的研发成果，并获得 FDA 快速通道认证，预示着其潜在的临床价值和市 场前景。 迪哲医药 2025 年上半年营业收入同比增长 74%至 3.55 亿元，销售费 用率降低约 24%，显示出舒尔哲和高瑞哲通过医保赋能实现快速放量， 商业化增长势头强劲，盈利能力显著提升。 迪哲医药成功完成科创板八条后首家再融资发行，募集资金近 18 亿元， 现金储备增至 22.51 亿元，为核心在研产品的高效开发提供了坚实的资 金保障，缓解了投资人对公司现金流的担忧。 Q&A 2025 年上半年迪哲医药有哪些重要的里程碑事件？ 2025 年上半年，迪哲医药取得了一系列重要的里程碑事件。首先，今年 1 月， 舒尔哲（Shu ...

2025年半年报显示，公司营业收入达1316.71万元，同比增长11899.08%，主要得益于首个1类新药氘恩 扎鲁胺软胶囊获批上市，实现药品销售收入1306.88万元。 8月21日主力资金净流出573.18万元，近五日累计净流出965.56万元。 风险提示：股市有风险，投资需谨慎。 海创药业-U股价报61.39元，较前一交易日下跌1.08%。盘中最高触及63.29元，最低下探至61.10元，成 交额1.44亿元。 海创药业-U属于生物制品板块，专注于创新药研发。公司以靶向蛋白降解PROTAC技术和氘代技术为核 心，聚焦癌症、代谢性疾病等治疗领域。 ...

康辰药业股价报53.57元，较前一交易日下跌0.42元，跌幅0.78%。盘中最高触及55.09元，最低下探 53.34元，成交额1.87亿元。 康辰药业属于生物制品板块，专注于创新药研发。公司自主研发的KC1086片近日完成I期临床试验首例 受试者入组，该药物为赖氨酸乙酰转移酶6的小分子抑制剂，拟用于晚期实体瘤治疗。 风险提示：股市有风险，投资需谨慎。 8月21日主力资金净流入54.18万元，近五日主力资金净流出1.48亿元。 ...

在百济神州（北京）生物科技有限公司，李强了解有关新药研发情况，察看药物化学实验室，细致询问 生产流程。李强说，我国健康产业市场空间巨大，创新药发展前景广阔。要及时发现临床价值高、转化 潜力大的创新药项目，加强跟踪服务，推动医疗机构配备使用。要大力培育优质企业，在人才、融资等 方面给予政策支持，鼓励企业深化国际合作，持续提升企业创新力、竞争力。 ● 新华社北京8月20日电（记者邹伟） 中共中央政治局常委、国务院总理李强8月20日在北京调研生物医药产业发展情况。他强调，要深入贯 彻习近平总书记关于生物医药产业发展的重要指示精神，加大高质量科技供给和政策支持，充分发挥企 业创新主体作用，着力推动生物医药产业提质升级，研发生产更多优质高效的好药新药，不断增进人民 健康福祉。 李强首先来到昌平实验室，听取有关重大疾病诊疗技术和设备设施研发进展汇报。李强指出，要在生物 医药这条新赛道上跑出加速度，必须加大科技创新力度。希望大家锚定国际前沿和重要领域，重点围绕 新靶点、新化合物、新作用机理等，集中协同开展科研攻关，多产出重大原创性成果，多培养生命科学 领域高端人才，不断夯实我国生物医药产业发展根基。 在北京飞镖国际创新中心 ...

Group 1 - The core business of the company is veterinary biological products, while the innovative drug pipeline, including AIDS monoclonal antibodies, is independently operated by its joint venture, Yangzhou Shizhi Source Biotechnology Co., Ltd. [2] - The related business has characteristics of long research and development cycles, high investment, and significant research risks [2]

Focus Review - The hard technology sector is seeing significant interest, particularly in intelligent robotics, with Daimon Robotics completing a financing round of over 100 million RMB led by China Merchants Venture Capital [4][15]. - The health sector continues to thrive, with RNA-targeted therapies and innovative drug development gaining traction. LiBo Bio announced nearly 100 million RMB in Pre-A financing, led by Tianshili Capital and Panlin Capital [4][23]. - In the internet sector, fintech is attracting attention, with FuBei Technology completing 50 million RMB in Pre-A financing led by GuanFeng Capital [5][29]. Hard Technology - ShiningSoul, a new cultural brand, completed a financing round of several hundred million RMB, led by Hillhouse Capital [7]. - Yushui Flying Technology secured nearly 10 million RMB in angel round financing from XBOTPARK Fund [8]. - New Voice Semiconductor completed 288 million RMB in B+ round financing, led by Hongtai Capital [14]. Health Sector - Zhejiang Haichang Bio announced nearly 500 million RMB in C round financing, led by the National Investment (Guangdong) Technology Transformation Fund [24]. - Beijing Zhiran Medical Technology completed over 300 million RMB in A round financing, led by the Social Security Fund and Junlian Capital [25]. Internet/Enterprise Services - Feidu Technology completed several million RMB in strategic financing, with investments from Longgang Financial Holdings and Daoshi Technology [28]. - ONERWAY, a global payment brand, completed 10 million USD in A+ round financing, with participation from Yunqi Capital and other investors [30].

Group 1 - The company has approved a special report on the storage and actual use of raised funds for the first half of 2025, ensuring compliance with relevant regulations [7][17][46] - The total amount raised from the public offering was RMB 1,062,699,200, with a net amount of RMB 995,113,315 after deducting issuance costs [7][25] - As of June 30, 2025, the company has used RMB 871,447,067.89 of the raised funds, with a remaining balance of RMB 147,244,678.39 [8][9] Group 2 - The company has adjusted the investment projects related to the raised funds, specifically suspending further development of the HP501 project due to market competition [27][31] - The remaining funds from the "Innovative Drug R&D Project" will be redirected to ongoing projects HP518 and HP537 [27][30] - The adjustments are aimed at improving the efficiency of fund usage and aligning with the company's long-term strategic goals [31][33] Group 3 - The company has decided to cancel its supervisory board, with its functions being transferred to the audit committee of the board of directors [48][69] - Amendments to the company's articles of association have been proposed to align with the new Company Law and improve governance [49][80] - The company has also revised several internal governance documents to enhance management efficiency and compliance with updated regulations [81]